BackMonte Rosa Therapeutics Overview

Monte Rosa Therapeutics Current Cash

Latest current cash for GLUE: $90M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$90.10M
↑ 29.78% YoYΔ $20.68M vs prior year quarter

Peer trimmed avg / median

Loading

Monte Rosa Therapeutics Current Cash History

Loading

Monte Rosa Therapeutics vs. peers: Current Cash Comparison

Loading

Monte Rosa Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Monte Rosa Therapeutics (GLUE) FAQ

Monte Rosa Therapeutics (GLUE) currently reports a current cash of $90M as of June 2026. That compares with $69M in the prior-year period — up 29.8% year over year. Use the charts on this page to explore Monte Rosa Therapeutics's current cash history and peer comparisons.

Monte Rosa Therapeutics's current cash increased from $69M to $90M — a 29.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics reported $90M in current cash as of June 2026. That compares with $69M in the prior-year period — up 29.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $90M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.

Monte Rosa Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $90M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLUE with unrelated industries.